Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.3 USD | +0.78% | -5.11% | -18.24% |
05-01 | HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target | MT |
03-18 | Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 1.7M 2.33M | Sales 2025 * | 2.11M 2.89M | Capitalization | 37.33M 51.28M |
---|---|---|---|---|---|
Net income 2024 * | -21M -28.85M | Net income 2025 * | -23M -31.59M | EV / Sales 2024 * | 22 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 17.7 x |
P/E ratio 2024 * |
-1.97
x | P/E ratio 2025 * |
-2.11
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.38% |
1 day | +0.78% | ||
1 week | -5.11% | ||
Current month | -10.96% | ||
1 month | +7.44% | ||
3 months | -25.71% | ||
6 months | +9.24% | ||
Current year | -18.24% |
Managers | Title | Age | Since |
---|---|---|---|
Charles Strattan
FOU | Founder | 78 | 90-08-08 |
Scott Fine
CEO | Chief Executive Officer | 67 | 14-01-31 |
Joshua Fine
DFI | Director of Finance/CFO | 42 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Fine
CEO | Chief Executive Officer | 67 | 14-01-31 |
Charles Strattan
FOU | Founder | 78 | 90-08-08 |
William Shanahan
BRD | Director/Board Member | 84 | 16-06-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 1.3 | +0.78% | 53,703 |
24-05-22 | 1.29 | -5.15% | 23,999 |
24-05-21 | 1.36 | -4.23% | 24,642 |
24-05-20 | 1.42 | +1.43% | 15,001 |
24-05-17 | 1.4 | +2.19% | 21,599 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.24% | 37.33M | |
+38.69% | 728B | |
+34.28% | 603B | |
-4.49% | 360B | |
+20.24% | 332B | |
+2.12% | 279B | |
+17.02% | 244B | |
+9.31% | 207B | |
-5.07% | 205B | |
-0.35% | 163B |
- Stock Market
- Equities
- CYTH Stock